Requirements for a lead compound to become a clinical candidate

Area of Science:

• Drug Discovery and Development
• Pharmacology
• Toxicology

Background:

• Transitioning a lead compound to a clinical drug candidate involves unique challenges.
• Predicting the timeline and cost of this phase is difficult due to program variability and common setbacks.
• Recent incidents of unpredicted human toxicity have heightened regulatory scrutiny and public demand for drug safety.

Purpose of the Study:

• To outline the critical criteria for a drug candidate suitable for clinical testing.
• To emphasize the importance of safety and regulatory compliance in drug development.
• To highlight the complexities and unpredictability of the lead-to-candidate transition.

Main Methods:

• Review of essential drug candidate characteristics: selective receptor binding, functional response, bioavailability, and biodistribution.
• Discussion of the idiosyncratic nature of the drug discovery and development pathway from lead to clinical candidate.
• Emphasis on formal toxicity evaluation in animals as a mandatory step.
• Analysis of the impact of recent unpredicted human toxicity incidents on regulatory standards.

Main Results:

• A successful drug candidate must demonstrate selective receptor interaction and elicit the desired biological effect.
• Adequate bioavailability and biodistribution are crucial for efficacy in preclinical and clinical settings.
• Formal toxicity evaluation is a non-negotiable requirement for regulatory approval.
• Safety considerations have become the dominant factor in identifying clinical drug candidates.

Conclusions:

• The journey from a lead compound to a clinical drug candidate is highly variable and prone to setbacks.
• Stringent regulatory and public safety demands prioritize toxicity evaluation and risk assessment.
• Ensuring drug safety is the most critical determinant in advancing a candidate for clinical trials.